Clinical trials: MGMT-Unmethylated Glioblastoma
Glioblastoma
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT…
- Trial name
- GLORIA (NCT04121455)
- Testing
- Olaptesed pegol, Radiotherapy, Bevacizumab
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- TME Pharma AG
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme, MGMT-Unmethylated Glioblastoma
Repurposing Chlorpromazine in the Treatment of Glioblastoma
This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol, i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide, in…
- Trial name
- RACTAC (NCT04224441)
- Testing
- Chlorpromazine Pill
- Where
- 3 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Marco G Paggi, MD, PhD
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
MGMT-Unmethylated Glioblastoma
Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited.
- Trial name
- NCT05694416
- Testing
- Etoposide Plus Cisplatin
- Volunteers
- 60 people
- Sponsor
- Zhongnan Hospital
Primary Glioblastoma
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Glioblastomas (GBM) are the most frequent brain tumors and one of the most lethal adult cancers despite maximal multimodal therapy.
- Trial name
- MATVAC-1 (NCT07347210)
- Testing
- UCPVax, Pembrolizumab, Temozolomide
- Where
- 4 sites in France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma.
- Trial name
- NCT07452458
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 54 sites in United States
- Volunteers
- 398 people
- Sponsor
- NRG Oncology
EGFR Gene Mutation, Glioblastoma
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma.
- Conditions
- EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Trial name
- NCT06186401
- Testing
- E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hideho Okada, MD, PhD
Glioblastoma, Gliosarcoma
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
This phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or…
- Trial name
- NCT04555577
- Testing
- Peposertib, Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
This is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- TEM-GBM (NCT03866109)
- Testing
- Temferon
- Where
- 3 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Genenta Science
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma.
- Trial name
- NCT05879250
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Northwestern University
Glioblastoma
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
The investigators propose to conduct a multicenter, open-label, randomized, phase II study in patients with newly diagnosed glioblastoma (CeCil).
- Trial name
- NCT01044225
- Testing
- Cetuximab, Cilengitide EMD 121974
- Where
- 6 sites in Belgium
- Volunteers
- 12 people
- Sponsor
- Bart Neyns
Glioblastoma, Glioma, Malignant
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM
The primary purpose of this study is to determine the maximum tolerated dose (MTD) of MT-201-GBM (pp65CMV antigen monocytes) that will be administered to patients newly diagnosed with a type of brain tumor called glioblastoma…
- Trial name
- DEMAND (NCT04741984)
- Testing
- MT-201-GBM monocyte vaccine
- Sponsor
- Michael Gunn
Glioblastoma, Gliosarcoma
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
This phase I trial studies the side effects and best dose of tinostamustine (EDO-S101) given with or without radiation therapy in treating patients with newly diagnosed MGMT-unmethylated glioblastoma.
- Conditions
- Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT03452930
- Testing
- Radiation Therapy, Tinostamustine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Glioma, Glioblastoma
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in combination with a standard of care radiation regimen when used to treat newly diagnosed GBM…
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT03050736
- Testing
- VAL-083 (Dianhydrogalactitol)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Kintara Therapeutics, Inc.
Glioblastoma
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
This is an open-label phase 1 study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as…
- Trial name
- NCT06973096
- Testing
- CART-EGFR-IL13Ra2 cells, Rituximab or Rituximab biosimilar, Fludarabine + Cyclophosphamide combination
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Newly Diagnosed MGMT Unmethylated Glioblastoma
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease…
- Trial name
- NCT05734560
- Testing
- D2C7-IT, 2141-V11
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Darell Bigner
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Glioblastoma
Azeliragon in MGMT Unmethylated Glioblastoma
This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma.
- Trial name
- NCT05986851
- Testing
- Azeliragon
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cantex Pharmaceuticals